You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

The Vista+™ MC Product Advantage

The early rationale for the injection of intraocular agents (e.g. ranibizumab) was to inhibit growth of new pathological blood vessels.

The rationale for the injection of glucocorticoids (e.g. triamcinolone) is to supress inflammation; both new vessels and inflammation resulting in retinal oedema.

The novel thinking behind Eye Co's use of mineralocorticoids (Vista+™ MC) is to target retinal barrier leakage (oedema) directly. Additionally, the use of mineralocorticoids is expected to reduce the risk of increased intraocular pressure and cataract progression, which are major restrictions to the intraocular application of glucocorticoids. The MR class, properly formulated and targeted, promises the clinician all the benefits of ocular steroids, with fewer side effects. This invention focuses on the administration of compounds to treat, ameliorate or prevent ophthalmic conditions in both the anterior and posterior regions of the eye.

Front of Eye: Pterygium, Conjunctivitis, Anterior Uveitis and ocular allergies are also some of the diseases targeted by Vista+™ MC. These diseases may involve the inflammation and proliferation of vascular tissue in the anterior section of the eye, causing leakage of fluids from blood vessels which invade the cornea and surrounding tissues resulting in corneal swelling and oedema.

Back of Eye: Exudative retinopathies treated by this technology include: diabetic macular oedema (DME), cystoid macular oedema (CMO) and Wet Age Related Macular Degeneration. Maculopathy, affecting the macula (i.e., the central region of the retina), may be present with varying degrees of severity in all forms of diabetic retinopathy. In most cases, maculopathy results from macular oedema arising from the gradual leakage of macular capillaries, cystoid macular oedema also occurs commonly after eye surgery and can also result from inflammatory eye conditions.